Mark Salvati - Regeneron | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 7 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Phase 1 Study of REGN6569, a GITR Mab, in Combination with Cemiplimab in Patients (pts) with Advanced Solid Tumor Malignancies: Initial Dose-Escalation Results

Nehal J. Lakhani,Omid Hamid,Irene Brana, M. Julia Lostes-Bardaji, Pablo Gajate, Maria Pilar Lopez-Criado,Paul Swiecicki, Maria J. de Miguel,Marta Gil-Martin,Victor Moreno, Aixa Elena Soyano Muller, Ana Gonzalez Ortiz, Dylan Sun, Dimple Modi, Wenjun Zheng,Vladimir Jankovic,Mark Salvati,Matthew G. Fury, Mihaela C. Cristea

Journal of Clinical Oncologyno. 16_suppl (2024): 2650-2650

引用0浏览0引用

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination with Cemiplimab in Advanced Melanoma

Omid Hamid,Karl D. Lewis,Amy Weise,Meredith McKean,Kyriakos P. Papadopoulos,John Crown,Tae Min Kim,Dae Ho Lee,Sajeve S. Thomas, Janice Mehnert,John Kaczmar,Nehal J. Lakhani,Kevin B. Kim, Mark R. Middleton,Guilherme Rabinowits, Alexander I. Spira,Melinda Yushak,Inderjit Mehmi, Fang,Shuquan Chen,Jayakumar Mani,Vladimir Jankovic, Fang Wang,Nathalie Fiaschi,Laura Brennan,Anne Paccaly, Sheila Masinde,Mark Salvati,Matthew G. Fury,Glenn Kroog,Israel Lowy, Giuseppe Gullo

JOURNAL OF CLINICAL ONCOLOGYno. 24 (2024)

引用0浏览0WOS引用

A Phase 2/3 Study of Fianlimab, Cemiplimab, Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Nashat Gabrail,Miranda Gogishvili,Tamta Makharadze, Nino Chikhladze, Nicole Faulkner,Santosh Nair,Emad Ibrahim, Daniel Brungs, Luke Dreisbach, Gopal Kunta,Solange Peters, Christopher Nguyen, Majed Ghattas,Siyu Li,Mark Salvati,Israel Lowy,Matthew G. Fury, Luca Paoluzzi,Tamar Melkadze

Journal of clinical oncologyno. 16_suppl (2024): TPS8660-TPS8660

引用0浏览0引用

PP01.85 A Phase 2/3 Study of Fianlimab, Cemiplimab, Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer

Nashat Gabrail, Neil Faulkner,Santosh Nair,Emad Ibrahim,Daniel Brungs, Luke Dreisbach, Gopal Kunta,Jayakumar Mani, Maria Ghattas, Siyu Li,Mark Salvati,Israel Lowy, Tara Hiley,Matthew G. Fury, Luca Paoluzzi

Journal of Thoracic Oncologyno. 7 (2024): e39

引用0浏览0引用

PP01.87 A Phase 2/3 Study of Fianlimab Plus Cemiplimab Versus Cemiplimab in Patients with Advanced NSCLC with Tumors Expressing PD-L1 ≥50%

Neil Faulkner,Santosh Nair,Nashat Gabrail, Gopal Kunta,Emad Ibrahim, Luke Dreisbach,Daniel Brungs,Jayakumar Mani, Maria Ghattas, Siyu Li,Mark Salvati,Israel Lowy, Tara Hiley,Matthew G. Fury, Luca Paoluzzi

Journal of Thoracic Oncologyno. 7 (2024): e39

引用0浏览0引用

A Phase 3 Trial of Fixed Dose Combinations of Fianlimab (Anti–lag-3) + Cemiplimab (Anti–pd-1) Versus Relatlimab + Nivolumab in Patients with Unresectable or Metastatic Melanoma

Nikhil I. Khushalani,Jayakumar Mani,Jocelyn Booth, Zoe Zhang,Mark Salvati,Israel Lowy,Matthew G. Fury,Karl D. Lewis, Garen Manvelian, Hussein A. Tawbi

Journal of clinical oncologyno. 16_suppl (2024): TPS9611-TPS9611

引用0浏览0引用

PPD01.86 Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination with Cemiplimab in Advanced NSCLC

Byoung Chul Cho, Grace K. Dy, Tae Min Kim, Debashis Sarker, Omid Hamid, Stephen K. Williamson, Sang-We Kim, Hatim Husain, Fang, Shuquan Chen,Jayakumar Mani, Vladimir Jankovic,Anne Paccaly, Sheila Masinde, Israel Lowy, Laura Brennan,Mark Salvati,Matthew Fury, Karl Lewis

Journal of Thoracic Oncologyno. 7 (2024): e8-e9

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn